Myriad Genetics (MYGN) Other Non-Current Assets (2010 - 2026)

Myriad Genetics has disclosed Other Non-Current Assets across 15 years of filings, most recently posting $5.6 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 27.27% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (down 27.27% YoY), while the FY2025 annual figure was $5.6 million, down 34.12% from the prior year.
• Other Non-Current Assets held at $5.6 million in Q1 2026, from $5.6 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for MYGN reached as high as $22.1 million in Q2 2023 and fell as low as $5.6 million in Q4 2025.
• The 5-year median for Other Non-Current Assets is $8.8 million (2022), against an average of $11.4 million.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 151.14% — and 2025, when it slumped 60.0%.
• A 5-year view of Other Non-Current Assets shows it stood at $15.5 million in 2022, then retreated by 0.65% to $15.4 million in 2023, then slumped by 44.81% to $8.5 million in 2024, then tumbled by 34.12% to $5.6 million in 2025, then changed by 0.0% to $5.6 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $5.6 million, $5.6 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.